| Literature DB >> 29271057 |
Jay P Reddy1, Mike Hernandez2, Jillian R Gunther1, Bouthaina S Dabaja1, Geoffrey V Martin1, Wen Jiang1, Mani Akhtari1,3, Pamela K Allen1, Bradley J Atkinson4, Grace L Smith1, Chelsea C Pinnix1, Sarah A Milgrom1, Zeinab Abou Yehia1, Eleanor M Osborne1, Yasuhiro Oki5, Hun Lee5, Fredrick Hagemeister5, Michelle A Fanale5.
Abstract
To determine whether pre-treatment neutrophil/lymphocyte (NLR) or platelet/lymphocyte ratios (PLR) are predictive for progression in early-stage classical Hodgkin lymphoma (cHL), we derived NLR and PLR values for 338 stage I/II cHL patients and appropriate cut-off point values to define progression. Two-year freedom from progression (FFP) for patients with NLR ≥6·4 was 82·2% vs. 95·7% with NLR <6·4 (P < 0·001). Similarly, 2-year FFP was 84·3% for patients with PLR ≥266·2 vs. 96·1% with PLR <266·2 (P = 0·003). On univariate analysis, both NLR and PLR were significantly associated with worse FFP (P = 0·001). On multivariate analysis, PLR remained a significant, independent prognostic factor (P < 0·001).Entities:
Keywords: Hodgkin lymphoma; lymphocyte; neutrophil; platelet; refractory; relapse
Mesh：
Year: 2017 PMID： 29271057 DOI： 10.1111/bjh.15054
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998